Literature DB >> 21542742

Radical prostatectomy versus watchful waiting in early prostate cancer.

Anna Bill-Axelson1, Lars Holmberg, Mirja Ruutu, Hans Garmo, Jennifer R Stark, Christer Busch, Stig Nordling, Michael Häggman, Swen-Olof Andersson, Stefan Bratell, Anders Spångberg, Juni Palmgren, Gunnar Steineck, Hans-Olov Adami, Jan-Erik Johansson.   

Abstract

BACKGROUND: In 2008, we reported that radical prostatectomy, as compared with watchful waiting, reduces the rate of death from prostate cancer. After an additional 3 years of follow-up, we now report estimated 15-year results.
METHODS: From October 1989 through February 1999, we randomly assigned 695 men with early prostate cancer to watchful waiting or radical prostatectomy. Follow-up was complete through December 2009, with histopathological review of biopsy and radical-prostatectomy specimens and blinded evaluation of causes of death. Relative risks, with 95% confidence intervals, were estimated with the use of a Cox proportional-hazards model.
RESULTS: During a median of 12.8 years, 166 of the 347 men in the radical-prostatectomy group and 201 of the 348 in the watchful-waiting group died (P=0.007). In the case of 55 men assigned to surgery and 81 men assigned to watchful waiting, death was due to prostate cancer. This yielded a cumulative incidence of death from prostate cancer at 15 years of 14.6% and 20.7%, respectively (a difference of 6.1 percentage points; 95% confidence interval [CI], 0.2 to 12.0), and a relative risk with surgery of 0.62 (95% CI, 0.44 to 0.87; P=0.01). The survival benefit was similar before and after 9 years of follow-up, was observed also among men with low-risk prostate cancer, and was confined to men younger than 65 years of age. The number needed to treat to avert one death was 15 overall and 7 for men younger than 65 years of age. Among men who underwent radical prostatectomy, those with extracapsular tumor growth had a risk of death from prostate cancer that was 7 times that of men without extracapsular tumor growth (relative risk, 6.9; 95% CI, 2.6 to 18.4).
CONCLUSIONS: Radical prostatectomy was associated with a reduction in the rate of death from prostate cancer. Men with extracapsular tumor growth may benefit from adjuvant local or systemic treatment. (Funded by the Swedish Cancer Society and the National Institutes of Health.).

Entities:  

Mesh:

Year:  2011        PMID: 21542742     DOI: 10.1056/NEJMoa1011967

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  253 in total

1.  A new standard for radical prostatectomy in Ireland?

Authors:  D G Murphy
Journal:  Ir J Med Sci       Date:  2012-01-11       Impact factor: 1.568

2.  Health-related quality of life outcomes in Scandinavian patients after radical prostatectomy or watchful waiting: a critical appraisal.

Authors:  Andrea A Chan; Steven E Canfield; Run Wang
Journal:  Asian J Androl       Date:  2011-11-07       Impact factor: 3.285

Review 3.  [What can medicine expect from health economics?].

Authors:  E Bismarck; B J Schmitz-Dräger; O Schöffski
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

4.  Natural orifice translumenal endoscopic radical prostatectomy.

Authors:  Mitchell R Humphreys; Erik P Castle; Paul E Andrews; James E Lingeman
Journal:  Ther Adv Urol       Date:  2012-02

5.  Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?

Authors:  D Andrew Loblaw
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

Review 6.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

7.  A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Authors:  M A Liss; J M Schenk; A V Faino; L F Newcomb; H Boyer; J D Brooks; P R Carroll; A Dash; M D Fabrizio; M E Gleave; P S Nelson; M L Neuhouser; J T Wei; Y Zheng; J L Wright; D W Lin; I M Thompson
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

Review 8.  Challenging treatment decision-making in older urologic cancer patients.

Authors:  Guillaume Ploussard; Gilles Albrand; François Rozet; Hervé Lang; Elena Paillaud; Pierre Mongiat-Artus
Journal:  World J Urol       Date:  2013-08-30       Impact factor: 4.226

9.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

Review 10.  Locally advanced prostate cancer: optimal therapy in older patients.

Authors:  Michael Froehner; Manfred P Wirth
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.